Info Sheet

Independent Asset Review

Strategic Support for Critical Phase III Go/No-Go Decisions

With a rising investment cost and a failure rate of over 50%, effectively identifying the risks of transitioning to Phase III development is essential. However, while many pharmaceutical companies work diligently to ensure they have effectively identified all areas of vulnerability, they often overlook the potential influence of ownership, investment, or optimism bias.

Advarra's independent asset reviews bring the objectivity required to effectively test critical assumptions and strategies related to the Phase III transition process. Mobilizing our subject matter experts' comprehensive, hands-on experience, we use data from the latest development studies, market research, regulatory feedback, and other sources to help our clients identify risks associated with moving forward with their Phase III program.

Download our info sheet to learn more about how an independent asset review can benefit your organization.

Who should watch?

text goes here

CEU Credits

text goes here

Certificate of Attendance

text goes here

Time: 1 p.m. ET, 12 p.m. CT, 10 a.m. PT
Duration: 1 hour

Download Now